A-PBITMO

From WikiProjectMed
Jump to navigation Jump to search
A-PBITMO
Identifiers
  • (Adamantan-1-yl)(3-pentyl-2-thioxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methanone
Chemical and physical data
FormulaC23H30N2OS
Molar mass382.57 g·mol−1
3D model (JSmol)
  • S=C1N(C(=O)C23CC4CC(C2)CC(C3)C4)c2ccccc2N1CCCCC

A-PBITMO is a synthetic cannabinoid receptor agonist that has been sold as a designer drug, first reported in Germany in July 2023,[1] and also subsequently identified in Russia.[2] It has an unusual 1,3-dihydrobenzimidazole-2-thione core structure which has not previously been seen in cannabinoid designer drugs.

See also

References

  1. ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
  2. ^ Yurchenko R, et al. Psychoactive products market observation. Trend analysis. Issue 50. February 2024. (in Russian) doi:10.13140/RG.2.2.10176.92163
Stub icon

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://mdwiki.org/wiki/A-PBITMO"